Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs SoundHound AI Inc (SOUN) Price & Performance

Citius Pharmaceuticals IncTrade
SoundHound AI IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs SoundHound AI Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while SoundHound AI Inc trades at $7.35 (market cap $3.29B). The key difference: SoundHound AI Inc is far larger — about 164.4× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

CTXRSOUN
Market Cap
$20.01M$3.29B
Sector
HealthTechnology
52-Week High
$1.82$21.40
52-Week Low
$0.48$5.70
Enterprise Value
$16.23M$3.09B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

SoundHound AI Inc

SOUN trades at $7.35, down 1.47% on the day, with a bullish technical signal from moving averages. The company reported strong revenue growth of 45% in Q2 2026 and raised its full-year outlook, driven by its OASYS platform. However, it remains unprofitable with a net income margin of -67.45% and negative cash flow from operations. Analyst sentiment is positive with a 75% buy rating and an $8.50 consensus price target.

The outlook hinges on SOUN's ability to convert rapid revenue growth into profitability. Investment opportunity lies in market leadership in voice AI and enterprise adoption via OASYS. Key risks include persistent cash burn, high valuation multiples, and execution challenges in integrating acquisitions like LivePerson.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About SoundHound AI Inc

SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.

Read more on SOUN